Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yaba daba dooo, grab a dab or dooob
Go CGC
I think the most important trades will be post q1 fy2019 and Year End fy2019, greatly assuming the legislation is passed. I also think Demand will be very high into 2019 when a whole new stream of Edible products come into market
Teeheeehee... Go CGC . I missed saying that
Not that my opinion of your trades matter, but I disagree.
In a growth industry/company like this, I’m looking for the volume in relationship to fundamental developments to set the support and resistance levels. Picture that. No Guru
I don’t think it’s baked in yet. I assume there is a deluge of volume demand waiting on the other side of the listing. Plus momentum...
For FQSakes, We missed the Big Green Nugget around here!
Friday would be a great way to close the StrongEnd
Opening Bell Tomorrow Morning maybe?
I’m concerned as to wether or not protocol is being followed for disseminating sensitive information for a public corporation. Not to tamper excitement, just no need for any yellow cards at this stage of the game.
The question is wether it is “Federally “ permissible to trade in the growing and processing of Cannabis (CBD) and derivatives in USA. As of today, I can purchase Cannabis, Shatter, all types of derivatives from any of a thousand dispensaries in any province in Canada, but without an Growers permit or Lp licence or Dealers permit it’s not Federally permissible to do so.
Interesting, I did not know. Please post a reference. If CBD is already rescheduled at the Federal level, and legal for trade Im assuming, wouldn't that make it an available market for Canopy?
Order #84018x
May 22, 00:00 hrs PST
Adding to the speculation for 2018...
http://www.beckley-canopy.com/research.html
RESEARCH AND DEVELOPMENT Cannabis-based medicines offer a disruptive alternative to many of the standard treatments emanating from the $1.1 trillion dollar pharmaceutical industry. Thousands of years of evidence, millions of testimonies and dozens of clinical trials continue to prove that cannabis is a safe and effective treatment for a broad range of mental and physical diseases. Yet physician acceptance and subsequent consumer access to cannabis therapies continues to be restricted by the relative lack of rigorous clinical research data. A glaring clinical need exists for cannabis-based medicines that meet pharmaceutical standards of quality, consistency, and scientific validation.{...}
and,
{...}ONGOING RESEARCH BECKLEY CANOPY’s first IP generating research in humans is already underway: a brain imaging trial looking at the effects of a proprietary cannabinoid formulation in the treatment of a major indication. Additional research and product development programs are scheduled to start in 2018. As IP positions are secured, further information will be provided.
WAH! Jaw DROP!.... Im floored... Good for him... eh hem.....Id really like to here Awesome's take on this...
Unanimous Positive Result of FDA Advisory Committee Meeting for First Plant-Based Pharmaceutical Cannabidiol Treatment for Seizures in Patients with Two Rare, Severe Forms of Epilepsy
APR 18, 2018
https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-announces-unanimous-positive-result-fda-advisory-committee-meeting
{...FDA Advisory Committees are independent expert panels. Their votes are not binding but are considered by the FDA when deciding whether to approve a new medicine. The PDUFA (Prescription Drug User Fee Act) goal date for completion of the NDA review of the cannabidiol oral solution is June 27, 2018.
{...GW has submitted a New Drug Application with the FDA for Epidiolex as adjunctive treatment for seizures associated with LGS and Dravet syndrome, which has been assigned a goal date of 27 June 2018 and, if approved, the medicine is expected to be available by prescription in the second half of 2018.
...Bofore Mods Delete this post, I assume its relevance to Canopy Growth because : Approvals of CBD based formulations for specific indications by the FDA can lead to Federal rescheduling of CBD, therefore opening a significant market to Canopy Health Innovations and In turn Canopy Growth.
I’ve done some funny napkin calculations based market cap comparisons.... wildly speculating. But considering Netflix almost single handedly tipped an entire industry towards its revenue stream and debunked the Blockbuster oligarchs. Hmmm? Sound a bit like Cannabis? Hmmm...
Potential upcoming catalyst for Canopy:
1 : NYSE listing ( any day )
2 : Senate c45 vote ( June 7 ~ )
3 : GWP / FDA ruling on Epidiolex (June 27) (CBD Industry relevant)
4 : fy18 financials (~ June 29 )
... and the list goes on and on and on,
Please feel free to add to the speculation.
...After 6 months of combined recMJ and MMJ California which is apples to apples comparison on population with Canada will report its tax revenues. Hmmm...
Of course, to achieve a Global revenue stream for Cannabis like a Netflix or McDonalds will take time. But then when do you think is the best time to invest? Hmmm...
These Stats on Cannabis Sales Will Shock You
New projected numbers put the pot business on par with Netflix and McDonald's.
https://www.entrepreneur.com/article/313270
Jonathan Small
Contributor
May 21, 2018
If you weren't convinced that we are in the early stages of a cannabis boom unlike any other in history, then perhaps these numbers from Chris Walsh, an industry analyst and editorial vice president of MJBiZDaily, will change your mind.
Smith, who presented his findings to a packed crowd in April at The Marijuana Business Conference & Expo in New Orleans, said that retail sales of medical and recreational cannabis in the United States are expected to hit $8 billion-$10 billion this year. That's a nearly 50 percent increase from 2017.
Other interesting findings:
Cannabis outsells Oreos (and possibly McDonald's).
In 2017, sales of medical and recreational cannabis in the U.S. were nearly nine times higher than Oreo cookies, which puts cannabis almost on par with America’s collective spending on Netflix subscriptions. With the addition of California’s recreational market sales in 2018, cannabis sales could easily eclipse McDonald’s annual U.S. revenue.
Cannabis creates job surge.
The cannabis sector currently employs 125,000-160,00 full-time workers. "To put this in perspective, there are potentially more full-time marijuana industry workers that there are librarians or kindergarten teachers throughout the country--and over six times the number of coal
miners in the U.S," said Walsh.
He projects the industry to add as many as 340,000 full-time jobs by 2022. This reflects an estimated growth of 21 percent per year, significantly higher than official estimates for other industries and professions such as U.S. Healthcare, which is expected to grow 2 percent.
Cannabis is bigger than Bolivia.
The marijuana industry will create an estimated $28B-$34B economic impact in 2018. That's larger than the entire GDP of Bolivia. By 2022, cannabis sales could soar past $75B annually.
Cannabis may nick cigarettes.
Total demand for marijuana in the U.S., including the black market, is around $52.5 billion. If the federal government legalized marijuana nationwide, eventually, marijuana could surpass cigarette sales--with the potential to rival beer in terms of overall sales.
Are you ready for legal marijuana?
Going live in *(correction)* * 1 Hour **
For your listening interest:
Cross Country Checkup
http://www.cbc.ca/radio/checkup/are-you-ready-for-legal-marijuana-1.4659925
Sunday on Cross Country Checkup: legal pot
The government has delayed its plans to legalize marijuana once, and it's under pressure to delay again.
Concerns about the details are still rolling in from Indigenous groups to doctors, from schools to the police, and even real estate vendors.
Our question: Are you ready for legal marijuana?
Join Duncan McCue, Sunday live simultaneously through six time zones on CBC Radio One, Sirius XM channel 169, and streaming on cbc.ca and on the CBC Radio app.
1 p.m. PT, 2 p.m. MT, 3 p.m. CT, 4 p.m. ET, 5 p.m. AT, 5:30 p.m. NT.
Toll-free number during the broadcast: 1-888-416-8333
Email: checkup@cbc.ca
Twitter: @checkupcbc
Facebook: CBC Cross Country Checkup
For your listening interest:
Cross Country Checkup
Are you ready for legal marijuana?
http://www.cbc.ca/radio/checkup/are-you-ready-for-legal-marijuana-1.4659925
Sunday on Cross Country Checkup: legal pot
The government has delayed its plans to legalize marijuana once, and it's under pressure to delay again.
Concerns about the details are still rolling in from Indigenous groups to doctors, from schools to the police, and even real estate vendors.
Our question: Are you ready for legal marijuana?
Join Duncan McCue, Sunday live simultaneously through six time zones on CBC Radio One, Sirius XM channel 169, and streaming on cbc.ca and on the CBC Radio app.
1 p.m. PT, 2 p.m. MT, 3 p.m. CT, 4 p.m. ET, 5 p.m. AT, 5:30 p.m. NT.
Toll-free number during the broadcast: 1-888-416-8333
Email: checkup@cbc.ca
Twitter: @checkupcbc
Facebook: CBC Cross Country Checkup
It’s almost unimaginable to me. Don’t mean to be pessimistic, I do hope for it. Just not convinced of the judicial and political conviction to do so. I prefer to be wrong in the near future.
I’ve submitted my application. Here’s to future growth
MERCH! One for everyone and two for myself!
Order #79796x. 00:50 4/20am
Rivers is already cfp, Perlsteins last analysis a buy and Pt of 12 months /$45 for Canopy Growth. Potential Ipo for Rivers in the pipeline. Maybe time to gather up some funds
Umm, has anyone here gotten the Memo that “ analyst Daniel Perlstein has left Firm Eight Capital and joined Canopy Rivers Corp. as it’s head of business development.”
- Christina Pellegrini ,
Street Wise - Globe And Mail
April 10, 2018.
Need I say the nuance of this development is ... very interesting
My guess is Sleep Aid, based on trinket mentions here and there over many moons past.
“The Global Sleep Aids Market was worth $59.6 billion in 2016 and estimated to be growing at a CAGR of 6.32%, to reach $83.8 billion by 2021.”
https://www.marketdataforecast.com/market-reports/global-sleep-aids-market-1790/
Most indicators and opinions point to everything in inventory today being sold by end of 2018, (Supply Agreements/MOU’s). Many other Lp’s and Late stage applicants won’t be even nearly ready to meet that demand this year or next. They’re playing catch-up while Canopy is setting the trends. 70% seems to be a wild figure, without reference. But based on ability to meet demand across Canada, I do imagine meeting Majority portion of supply.
A very close friend of mine was hired by an Alberta Lp, to do practical use testing on Hemp Fibre Building blocks; the cousin to the Portland Cement cinder block currently used in all structural masonry applications. His take away was that although very lightweight and high in R Value, they remain impractical for structural application, due its high porosity and a few other engineering flaws. With experience in building, I agree. Although for architectural applications, they are definitely a viable contender. There may or may not be a Hemp revolution. Big money would have to see big savings, other than feel good applications as a raw material. From Paper and Pulp to clothes fibre, we already have the opportunity to use hemp. Maybe an over production to drastically reduce its commodity price will recreate forgotten industries for the raw material. Who knows. Can there be a Hemp Revolution to follow the industrial revolution?
Corporate social responsibility update from Canopy Growth, Canadian Students for Sensible Drug Policy and Parent Action on Drugs
https://www.newswire.ca/news-releases/corporate-social-responsibility-update-from-canopy-growth-canadian-students-for-sensible-drug-policy-and-parent-action-on-drugs-678736543.html
Introducing Sensible Cannabis Education: A Toolkit for Educating Youth
SMITHS FALLS, ON and TORONTO, April 4, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is dedicated to using its platform and resources towards meaningful CSR initiatives related to cannabis and society. Today, the Company wishes to recognize Canadian Students for Sensible Drug Policy ("CSSDP") which, with the support of an unrestricted grant from Canopy Growth, has compiled a comprehensive cannabis education toolkit aimed at youth. focuses on realistic and evidence-based approaches to cannabis education for young Canadians.
It is critical to support parents and educators in their ability to communicate with youth, and educate young adults on how to make healthy, responsible decisions on the use of cannabis. Created for educators and parents alike, Sensible Cannabis Education: A Toolkit for Educating Youth, provides a contextual support to adults who aim to have an informed and non-judgmental conversation with youth on cannabis responsibility.
The comprehensive toolkit addresses and contextualizes concerns surrounding issues such as: cognition, schizophrenia, lung cancer, IQ/intelligence, and frequency of use, in addition to addressing false narratives surrounding cannabis use. The toolkit also provides its readers with a framework of core concepts and values that are critical to how we approach drug education and cannabis conversations with youth from the outset. Young participants were actively involved and played an essential role in the creation of this important resource.
"Our Corporate Social Responsibility strategy is based on listening to communities and stakeholders and supporting areas where awareness and education can make positive contributions to society," said Mark Zekulin, President, Canopy Growth. "Working with partners like PAD and CSSDP, we can use our resources to make a difference for young people in Canada and around the world."
"Young people have a right to access and be involved in the creation of evidence-based education on cannabis, which is key to the development of youth's health literacy in a rapidly changing legal context," said Jenna Valleriani, Strategic Advisor, Canadian Students for Sensible Drug Policy. "Protecting all young people means including supports for youth who don't use cannabis, but also those who will use cannabis no matter what resource is provided to them. We believe this toolkit is an important first step towards that mandate and can inform Canada's efforts in developing pragmatic cannabis education, assist adults in having conversations about cannabis, and ground some of the common concerns and misconceptions around youth and cannabis use."
Canopy Growth has established partnerships with CSSDP, and Parent Action on Drugs ("PAD") with the primary objective of supporting parents and educators in their ability to communicate with young people and educate older youth to make healthy, responsible decisions about cannabis use. PAD, along with its extensive network and reach, brings thirty years' experience developing and providing evidence-based resources and programs for youth, families and professionals concerned with substance use.
"PAD's philosophy has always been to provide youth with the facts to enable them to make informed decisions about their drug use. This evidence-based cannabis toolkit provides important facts and information to increase knowledge as well as guidance on the approaches best suited to positively influence beliefs and motivations among youth," said Joanne Brown, Executive Director, Parent Action on Drugs. "PAD would like to thank the CSSDP for their extensive work on this comprehensive cannabis toolkit. Going forward, it will inform PAD's work on the development of accessible, interactive on-line resources. These tools will be designed to both educate and facilitate dialogue among parents and youth about cannabis use and associated risks. Our aim is to promote youth well-being."
The support of this important educational toolkit builds on the Corporate Social Responsibility work that Canopy Growth continues to conduct with other national partners including MADD Canada to address cannabis-impaired driving, and the Canadian AIDS Society to develop clinical cannabis guidelines for healthcare professionals.
Here's to Future Growth.
Nail biting. Very upsetting to see that even in the senate, the conservative caucus is still playing politics with this, opposing for opportunity and not based on principal. If I ever considered voting for conservatives, that notion is gone, seeing their political opportunism is of greater importance than progressiveness. I hope the independent senators don’t let that “standing vote” surprise them again.
Plenty of high cbd , low thc strains out there. Don’t drink the of cognac when your used to coolers. That’s part of Legalization, Education
Seriously Laughing Out Loud! This is ...Awesome! ...Clonk!
Hi, I’ve been watching this company since March 2014, then it ipo’d in April. Been as low as $1.08. Four years now. I haven’t bought a single share, just to see what would happen. Can’t be sure about anything nowadays. People on this board have been posting lots of great DD.
I’m wondering if now is the time to buy? Or should I wait for the legislation to pass? Or the P/E to come way down to normal levels? I figure if I had invested in the company since 2014 ish, when they started their phenomenal execution , the return on a hold strategy might be in excess of 800%. Wow. I missed the boat on that one. But I sure did read and Learn a lot of information and thoroughly entertaining.
But with all that said and read, I’m not sure. Awesome has been saying Legalization won’t happen, and there’s still a chance , and many on this board like Mr Clonk think it’s due for a beat down. What to do?
Bmo is invested at $34 ish. Snp/Tsx has Canopy’s in the exchange. All the provinces are planning thoroughly and spending big to ready up. The house voted well in favor and the senate seems to be giving it a real shot in the final committee stage readings.
Maybe, just to be sure, I’ll wait a little longer. At least until September, when for sure Legalization is in place and go from there. I can shop around for bargains then. I’d like to get at least a 2% return y.o.y to justify selling mutual funds to invest in Canopy. What do you think? A 50k investment can yield at least 1k! What do you think. Or should I wait until the end of fiscal 2019? Then for sure I would know exactly how much revenue and margin Canopy generates. You know, fully derisk. 0 risk , maximizing profit. Who knows what the sp will be then. But at least I’ll be sure... right?
Psych
Short Canopy? Don't want no short short man
don't, don't, don't, don't, Want no short short Man
don't, don't, don't, don't, want no short man
Innie Weeny teeny weeny shriveled little short short man
Innie weeny teeny weeny shriveled little short short man
Innie Weeny teeny weeny shriveled little short short man
Innie weeny teeny weeny shriveled little short short man
What in the world is that thing
Do need Tweezers to put that little thing away
That has got to be the smallest I've the seen... In my whole life
Get the Fuck outta here
Innie Weeny teeny weeny shriveled little short short man
Innie weeny teeny weeny shriveled little short short man
Innie Weeny teeny weeny shriveled little short short man
Innie weeny teeny weeny shriveled little short short man
ahh
ahh
ahh ahh ahh
don't, don't, don't, don't, Want no short short Man
don't, don't, don't, don't, want no short man
Innie Weeny
Innie Weeny
Innie Weeny
Innie Weeny teeny weeny shriveled little short short man
pobre pobrecito que diablo es eso
pobre pobreci pobre pobrecito que que que que que diablo es eso
don't, don't, don't, don't,
don't, don't, don't, don't,
don't, don't, don't, don't,
don't, don't, don't, don't,
ahh ahh ahh
Written by: Manfred MohrCarlos E. Rosario
. Introduction to the Endocannabinoid System
Dustin Sulak, DO
http://norml.org/library/item/introduction-to-the-endocannabinoid-system
As you read this review of the scientific literature regarding the therapeutic effects of cannabis and cannabinoids, one thing will become quickly evident: cannabis has a profound influence on the human body. This one herb and its variety of therapeutic compounds seem to affect every aspect of our bodies and minds. How is this possible?
At our integrative medical clinics in Maine and Massachusetts, my colleagues and I treat over 18,000 patients with a huge diversity of diseases and symptoms. In one day I might see cancer, Crohn's disease, epilepsy, chronic pain, multiple sclerosis, insomnia, Tourette syndrome and eczema, just to name a few. All of these conditions have different causes, different physiologic states, and vastly different symptoms. The patients are old and young. Some are undergoing conventional therapy. Others are on a decidedly alternative path. Yet despite their differences, almost all of my patients would agree on one point: cannabis helps their condition.
As a physician, I am naturally wary of any medicine that purports to cure-all. Panaceas, snake-oil remedies, and expensive fads often come and go, with big claims but little scientific or clinical evidence to support their efficacy. As I explore the therapeutic potential of cannabis, however, I find no lack of evidence. In fact, I find an explosion of scientific research on the therapeutic potential of cannabis, more evidence than one can find on some of the most widely used therapies of conventional medicine.
At the time of this writing (February 2015), a PubMed search for scientific journal articles published in the last 20 years containing the word "cannabis" revealed 8,637 results. Add the word "cannabinoid," and the results increase to 20,991 articles. That's an average of more than two scientific publications per day over the last 20 years! These numbers not only illustrate the present scientific interest and financial investment in understanding more about cannabis and its components, but they also emphasize the need for high quality reviews and summaries such as the document you are about to read.
How can one herb help so many different conditions? How can it provide both palliative and curative actions? How can it be so safe while offering such powerful effects? The search to answer these questions has led scientists to the discovery of a previously unknown physiologic system, a central component of the health and healing of every human and almost every animal: the endocannabinoid system.
What Is The Endocannabinoid System?
The endogenous cannabinoid system, named after the plant that led to its discovery, is perhaps the most important physiologic system involved in establishing and maintaining human health. Endocannabinoids and their receptors are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells. In each tissue, the cannabinoid system performs different tasks, but the goal is always the same: homeostasis, the maintenance of a stable internal environment despite fluctuations in the external environment.
Cannabinoids promote homeostasis at every level of biological life, from the sub-cellular, to the organism, and perhaps to the community and beyond. Here's one example: autophagy, a process in which a cell sequesters part of its contents to be self-digested and recycled, is mediated by the cannabinoid system. While this process keeps normal cells alive, allowing them to maintain a balance between the synthesis, degradation, and subsequent recycling of cellular products, it has a deadly effect on malignant tumor cells, causing them to consume themselves in a programmed cellular suicide. The death of cancer cells, of course, promotes homeostasis and survival at the level of the entire organism.
Endocannabinoids and cannabinoids are also found at the intersection of the body's various systems, allowing communication and coordination between different cell types. At the site of an injury, for example, cannabinoids can be found decreasing the release of activators and sensitizers from the injured tissue, stabilizing the nerve cell to prevent excessive firing, and calming nearby immune cells to prevent release of pro-inflammatory substances. Three different mechanisms of action on three different cell types for a single purpose: minimize the pain and damage caused by the injury.
The endocannabinoid system, with its complex actions in our immune system, nervous system, and all of the body's organs, is literally a bridge between body and mind. By understanding this system we begin to see a mechanism that explains how states of consciousness can promote health or disease.
In addition to regulating our internal and cellular homeostasis, cannabinoids influence a person's relationship with the external environment. Socially, the administration of cannabinoids clearly alters human behavior, often promoting sharing, humor, and creativity. By mediating neurogenesis, neuronal plasticity, and learning, cannabinoids may directly influence a person's open-mindedness and ability to move beyond limiting patterns of thought and behavior from past situations. Reformatting these old patterns is an essential part of health in our quickly changing environment.
What Are Cannabinoid Receptors?
Sea squirts, tiny nematodes, and all vertebrate species share the endocannabinoid system as an essential part of life and adaptation to environmental changes. By comparing the genetics of cannabinoid receptors in different species, scientists estimate that the endocannabinoid system evolved in primitive animals over 600 million years ago.
While it may seem we know a lot about cannabinoids, the estimated twenty thousand scientific articles have just begun to shed light on the subject. Large gaps likely exist in our current understanding, and the complexity of interactions between various cannabinoids, cell types, systems and individual organisms challenges scientists to think about physiology and health in new ways. The following brief overview summarizes what we do know.
Cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Researchers have identified two cannabinoid receptors: CB1, predominantly present in the nervous system, connective tissues, gonads, glands, and organs; and CB2, predominantly found in the immune system and its associated structures. Many tissues contain both CB1 and CB2 receptors, each linked to a different action. Researchers speculate there may be a third cannabinoid receptor waiting to be discovered.
Endocannabinoids are the substances our bodies naturally make to stimulate these receptors. The two most well understood of these molecules are called anandamide and 2-arachidonoylglycerol (2-AG). They are synthesized on-demand from cell membrane arachidonic acid derivatives, have a local effect and short half-life before being degraded by the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Phytocannabinoids are plant substances that stimulate cannabinoid receptors. Delta-9-tetrahydrocannabinol, or THC, is the most psychoactive and certainly the most famous of these substances, but other cannabinoids such as cannabidiol (CBD) and cannabinol (CBN) are gaining the interest of researchers due to a variety of healing properties. Most phytocannabinoids have been isolated from cannabis sativa, but other medical herbs, such as echinacea purpura, have been found to contain non-psychoactive cannabinoids as well.
Interestingly, the cannabis plant also uses THC and other cannabinoids to promote its own health and prevent disease. Cannabinoids have antioxidant properties that protect the leaves and flowering structures from ultraviolet radiation - cannabinoids neutralize the harmful free radicals generated by UV rays, protecting the cells. In humans, free radicals cause aging, cancer, and impaired healing. Antioxidants found in plants have long been promoted as natural supplements to prevent free radical harm.
Laboratories can also produce cannabinoids. Synthetic THC, marketed as dronabinol (Marinol), and nabilone (Cesamet), a THC analog, are both FDA approved drugs for the treatment of severe nausea and wasting syndrome. Some clinicians have found them helpful in the off-label treatment of chronic pain, migraine, and other serious conditions. Many other synthetic cannabinoids are used in animal research, and some have potency up to 600 times that of THC.
Cannabis, The Endocannabinoid System, And Good Health
As we continue to sort through the emerging science of cannabis and cannabinoids, one thing remains clear: a functional cannabinoid system is essential for health. From embryonic implantation on the wall of our mother's uterus, to nursing and growth, to responding to injuries, endocannabinoids help us survive in a quickly changing and increasingly hostile environment. As I realized this, I began to wonder: can an individual enhance his/her cannabinoid system by taking supplemental cannabis? Beyond treating symptoms, beyond even curing disease, can cannabis help us prevent disease and promote health by stimulating an ancient system that is hard-wired into all of us?
I now believe the answer is yes. Research has shown that small doses of cannabinoids from cannabis can signal the body to make more endocannabinoids and build more cannabinoid receptors. This is why many first-time cannabis users don't feel an effect, but by their second or third time using the herb they have built more cannabinoid receptors and are ready to respond. More receptors increase a person's sensitivity to cannabinoids; smaller doses have larger effects, and the individual has an enhanced baseline of endocannabinoid activity. I believe that small, regular doses of cannabis might act as a tonic to our most central physiologic healing system.
Many physicians cringe at the thought of recommending a botanical substance, and are outright mortified by the idea of smoking a medicine. Our medical system is more comfortable with single, isolated substances that can be swallowed or injected. Unfortunately, this model significantly limits the therapeutic potential of cannabinoids.
Unlike synthetic derivatives, herbal cannabis may contain over one hundred different cannabinoids, including THC, which all work synergistically to produce better medical effects and less side effects than THC alone. While cannabis is safe and works well when smoked, many patients prefer to avoid respiratory irritation and instead use a vaporizer, cannabis tincture, or topical salve. Scientific inquiry and patient testimonials both indicate that herbal cannabis has superior medical qualities to synthetic cannabinoids.
In 1902 Thomas Edison said, "There were never so many able, active minds at work on the problems of disease as now, and all their discoveries are tending toward the simple truth that you can't improve on nature." Cannabinoid research has proven this statement is still valid.
So, is it possible that medical cannabis could be the most useful remedy to treat the widest variety of human diseases and conditions, a component of preventative healthcare, and an adaptive support in our increasingly toxic, carcinogenic environment? Yes. This was well known to the indigenous medical systems of ancient India, China, and Tibet, and as you will find in this report, is becoming increasingly well known by Western science. Of course, we need more human-based research studying the effectiveness of cannabis, but the evidence base is already large and growing constantly, despite the DEA's best efforts to discourage cannabis-related research.
Does your doctor understand the benefit of medical cannabis? Can he or she advise you in the proper indications, dosage, and route of administration? Likely not. Despite the two largest U.S. physician associations (American Medical Association and American College of Physicians) calling for more research, the U.S. Congress prohibiting federal interference in states' medical cannabis programs, a 5,000 year history of safe therapeutic use, and a huge amount of published research, most doctors know little or nothing about medical cannabis.
This is changing, in part because the public is demanding it. People want safe, natural and inexpensive treatments that stimulate our bodies' ability to self-heal and help our population improve its quality of life. Medical cannabis is one such solution. This summary is an excellent tool for spreading the knowledge and helping to educate patients and healthcare providers on the scientific evidence behind the medical use of cannabis and cannabinoids
http://www.cbc.ca/news/politics/government-cannabis-bill-live-die-vote-1.4586113
The government's cannabis bill faces outright defeat in the Senate today if it can't secure enough support from members of the Red Chamber.
According to an agreed timetable, senators will hold a vote at second reading of the bill today. If the opposition Tories cobble together enough votes to defeat C-45, the legislation would be effectively dead — meaning the government would have to restart the entire legislative process in the House.
If that happens, a summer timeline for legalization becomes much less likely.
Not only does Canopy have a proven track record of execution, the diversity is stellar. Also, wether Tweed Farms , Les Serres or B.C. Tweed, the Greenhouse Management experience also vast and proven.
THE TEAM
Our accomplishments to date are a result of our diversity. From horticultural experts to storied cannabis growers – Harvard MBAs to Cambridge law graduates – Ottawa Valley tech icons to Compassion Club pioneers. With no existing roadmap to success in the cannabis sector Canopy created its own, valuing IQ along with expertise, bringing together the types of people who go looking for opportunities to innovate. We were the first cannabis company to go public, the first to launch diversified growing platforms, and the first to bring together two major licensed cannabis producers under one roof.
We are proud of our accomplishments, and are always looking for the next first.
Here’s to Future Growth.
Excellent Post. Thank You
I think the oral [short window] testing should be part of federal labor code legislation and do away with urinalysis for thc. There’s many private and public companies that force employees to do piss tests pre employment and randomly throughout. A toke last week could make thousands of people unemployed. All the other impairments disappear over night.
Questions and Answers - Proposed legislation to amend the Criminal Code: Impaired driving [c-46]
http://www.justice.gc.ca/eng/csj-sjc/pl/sidl-rlcfa/qa-qr.html
[At first read, I can see good potential in this regulation. The oral fluid screening reduces the window of Thc detection to a few hrs as opposed days, weeks and even months from urinalysis. Without the scientific proof of impairment, I think the bill stands only on one foot, but that need is acknowledged here. A bit sketchy for law enforcement and the courts.]
Part 1: Drug-impaired driving
Oral fluid drug screeners
What are oral fluid drug screeners and how do they work?
Oral fluid drug screeners are devices that are able to detect the presence of some drugs in oral fluid, including THC, the main impairing component in cannabis.The device is inserted into the mouth of a driver, and once enough oral fluid is collected, the device indicates the presence or absence of drugs. These devices are fast, non-invasive, and highly accurate.
What drugs can oral fluid drug screeners detect?
They can detect THC from cannabis, as well as cocaine, and methamphetamine. These are the three most common impairing drugs found in Canadian drivers.
What would be the legal limit for cocaine?
The scientific advice on impairing drug-levels for cocaine is expected shortly. Before the legal limit is enacted, the offence of impaired driving would continue to apply to an individuals who is driving while impaired by cocaine (and other drugs). The proposed legislation would permit drugs, such as cocaine and others, and their impairing levels to be added by regulation as research develops. This will enable the government to move quickly to protect Canadians.
Could an oral fluid screener detect cannabis that was smoked a few days before?
Oral fluid drug screeners do not detect non-impairing components of cannabis, so they would provide a positive result only in situations where cannabis was recently consumed.
How accurate are the oral fluid drug screeners?
Scientific advice has indicated that oral fluid drug screeners are reliable in screening drivers for the presence of THC and some other impairing drugs. Before a drug screener is approved for use by law enforcement, it would be evaluated against a set of rigorous evaluation standards to ensure it is suitable for use by police officers.
Could second-hand cannabis smoke result in a driver testing positive for THC on an oral fluid drug screener?
This is very unlikely. Current scientific advice indicates that there is a very little risk that passive exposure will lead to a positive result on an oral fluid screener.
When would police be allowed to test drivers for cannabis on an oral fluid screener?
Police would be authorized to demand that a driver provide an oral fluid sample if the officer has a reasonable suspicion that the driver has drugs in their body. A reasonable suspicion would be based on objectively discernable facts, such as red eyes, muscle tremors, agitation, or speech patterns.
Why is mandatory screening proposed for alcohol but not for drugs?
Mandatory screening is not proposed for drugs to reflect the difference in the technology between the approved screening device for alcohol and the oral fluid drug screener. The drug screener takes longer than the alcohol screener and cannot convert a sample of oral fluid to a blood drug concentration. Additionally, it is expected that the results on the oral fluid screener will need to be combined with the facts that were used to develop reasonable suspicion to move the investigation forward.
What happens if a driver refuses to provide a sample?
Similar to when a person refuses to comply with a breath sample, they could be charged with the offence of failure to comply.
What would happen if a driver screens positive for a drug on a drug screener?
A positive result on an oral fluid drug screener would provide information to the police officer that would help in developing reasonable grounds to believe that a drug-impaired driving offence has been committed. It is expected that the observed signs of impairment at the roadside, combined with a positive sample on the oral fluid screening device, would be sufficient for an investigation to move forward.
Have the Oral Fluid Drug Screening Devices been tested?
Public Safety Canada, along with its law enforcement partners across the country, led a pilot project to test how well officers were able to use certain roadside drug testing devices on drivers, under different weather conditions, (for example, cold, rain, snow) and at night. The project involved training police in the use of devices that test oral fluid for the presence of certain drugs and how to use them in operational settings. The pilot project will help inform the development of national standards and ensure a comprehensive approach for the use of drug screening devices in the enforcement of drug-impaired driving. The findings from the pilot project will also help inform standard operating procedures and training for law enforcement. The pilot ended in March 2017 and results will be made public in the coming weeks.
What will the Oral Fluid Drug Screening Devices Pilot Project help to inform?
The pilot project documented the experiences and feedback from officers who participated in the project and will help inform the development of national standards and ensure a comprehensive approach for the use of drug screening devices in the enforcement of drug-impaired driving in Canada for specific classes of drugs. The pilot ended in March 2017 and results will be made public in the coming weeks.
How would a manufacturer of an oral fluid drug screening device know if their device is suitable for use in Canada?
The DDC has recently published the evaluation standards against which all devices must be evaluated in order to determine if they could be approved for use by the AGC.
New offences for legal drug limits
What new offences are being proposed?
Three new offences of being over a prohibited level of drugs within two hours of driving are proposed:
a summary conviction offence, for a lower level of drugs (precautionary)
a hybrid offence for impairing levels of some drugs
a hybrid offence for impairing levels of some drugs in combination with alcohol
For what drugs would the Government be proposing legal limits and at what level?
Legal limits would be set by regulation. For THC, the proposed levels are:
at or over 2 ng (nanograms) but under 5 ng of THC per ml (millilitre) of blood for the low level drug offence, a summary conviction offence
at or over 5 ng of THC per ml of blood for the drug alone hybrid offence
at or over 2.5 ng of THC per ml of blood combined with 50 mg of alcohol per 100 ml of blood for the drugs-with-alcohol hybrid offence
Levels for some other impairing drugs would be set at any detectable level. This includes LSD, 6-MAM (a metabolite of heroin), Ketamine, Phencyclidine (PCP), and Psilocybin/Psilocin (magic mushrooms). Scientific advice indicates that these drugs are incompatible with safe driving at any level.
What penalties are proposed for the new offences?
The proposed penalties for the summary conviction offence would be a maximum of $1,000. The proposed penalties for the two hybrid offences would be the same as for alcohol impaired driving.
These include mandatory minimum penalties of $1000 for a first offence, 30 days imprisonment for a second offence and 120 days imprisonment for a third offence.
How much cannabis can I consume before it’s unsafe to drive?
Unlike alcohol, the existing scientific evidence does not provide general guidance to drivers about how much cannabis can be consumed before it is unsafe to drive or how long a driver should wait to drive after consuming cannabis. Mixing driving with cannabis, or any other impairing drug, is not safe and poses a danger to our streets and highways.
How would the new offences affect individuals who have a medical authorization for cannabis?
The proposed new offences would apply to all drivers, including those with a medical authorization for cannabis. The goal of the legislation is to help keep Canadians safe from impaired drivers. Safe levels of THC are unknown so a precautionary approach is necessary.
How do these proposals compare with other jurisdictions?
Other jurisdictions have set legal limits for impairing drugs, including cannabis. Colorado and Washington have set a 5ng limit for THC and the United Kingdom has set a 2ng limit. These reforms would put Canada amongst the leaders in the world with respect to road safety.
Strengthening the legal framework
Does this legislation propose any other measures, in addition to new offences and oral fluid screening to strengthen the ability of the justice system to address drug-impaired drivers?
The Bill would also clarify that certified drug recognition evaluating officers do not need to be qualified as an expert to give opinion testimony at trial; provide a police officer the option to demand blood instead of a drug recognition evaluation where they have reasonable grounds to believe an impaired driving offence has occurred; and, create a rebuttable presumption (i.e., a tool which helps Crown prove a specific fact through the proof of another fact) to better link the drug found in the drivers’ body with observed signs of impairment at time of driving.